Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22795875 | 0.98 | OPRM1 (0.39) | OPRM1OPRD1OPRK1OPRL1GRM2 | |
| SCHEMBL20621398 | 0.98 | OPRM1 (0.39) | OPRM1OPRD1OPRK1OPRL1GRM2 | |
| SCHEMBL9285009 | 0.93 | OPRM1 (0.43) | OPRM1OPRD1OPRK1OPRL1AOC3 | |
| SCHEMBL9233930 | 0.93 | OPRM1 (0.43) | OPRM1OPRD1OPRK1OPRL1AOC3 | |
| SCHEMBL14607991 | 0.86 | AOC3 (0.41) | AOC3 | |
| SCHEMBL779646 | 0.86 | AOC3 (0.41) | AOC3 | |
| SCHEMBL21555784 | 0.85 | OPRM1 (0.39) | OPRM1OPRD1OPRK1OPRL1GRM2 | |
| SCHEMBL19101512 | 0.85 | OPRM1 (0.39) | OPRM1OPRD1OPRK1OPRL1GRM2 | |
| SCHEMBL21555772 | 0.83 | OPRM1 (0.41) | OPRM1OPRD1OPRK1OPRL1GRM2 | |
| SCHEMBL7471746 | 0.83 | OPRM1 (0.39) | OPRM1OPRD1OPRK1OPRL1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITÉ DE TOURS (FR) | 2023-10-05 | — | — | US | disclosed |
| US-10221161-B2 | Inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-03-05 | — | — | US | disclosed |
| US-9926285-B2 | Allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME CORP. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9840481-B2 | Allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170275260-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221161-B2 | Inhibitors of plasma kallikrein | KLKB1, SERPINB1, KLK5 | OPRM1 3734/4885OPRD1 3300/4885OPRK1 2352/4885 |
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | LIMK1, LIMK2, ROCK1 | OPRM1 1510/4885OPRD1 420/4885OPRK1 117/4885 |
| US-20170275260-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | OPRM1 69/4885OPRD1 54/4885OPRK1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.